Subscribe to Updates in Healthcare

RSS By Email

RSS By RSS

Add to Google Reader or Homepage

Subscribe in Bloglines


The Expertise Imperative and Compliance Technology
Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.Learn more about GLG's Compliance Framework


This page may include content provided by Council Members, your access to which is subject to the Terms of Use.
Find Out More

All GLG News Analyses Filed Under: Cardiology

Articles with lock require a GLG News subscription
Posted September 5, 2007
Germany Bans Use of Cough Drugs With Clobutinol
Analysis of: Germany Bans Use of Cough Drugs With Clobutinol | www.medscape.com
Author: GLG Member Program Contributor
Clobutinol, a centrally acting cough suppressant (meaning that it works at the level of the brain to suppress the cough reflex), was voluntarily withdrawn from the marketplace by B.I., and now officially banned by a German regulatory agency, following reports that the drug may precipitate life-threatening...
Posted September 4, 2007
Nasal Decongestants Get New Sales Restrictions, UK
Analysis of: Nasal Decongestants Get New Sales Restrictions, UK | www.medicalnewstoday.com
Author: GLG Member Program Contributor
The MHRA -- the UK's version of the FDA -- is pondering action to restrict the volume of sales of pseudoephedrine and ephedrine, two OTC nasal decongestant products with amphetamine properties. The motivation behind the recommendation is a hope to curtail the rampant black market production of...
Posted September 4, 2007
St. Jude Medical Announces Japanese Approval Of The Angio-Seal STS Plus Vascular Closure Device
Analysis of: St. Jude Medical Announces Japanese Approval Of The Angio-Seal STS Plus Vascular Closure Device | www.medicalnewstoday.com
Author: GLG Member Program Contributor
St. Jude Medical has greatly modified their Angioseal closure device over the years to provide a device that is both efficacious and user friendly.  One of the difficulty with previous versions was the multiple steps, but with the STS platform, they have created a device that provides complete...
Posted September 3, 2007
Nasal Decongestants Get New Sales Restrictions, UK
Analysis of: Nasal Decongestants Get New Sales Restrictions, UK | www.medicalnewstoday.com
Author: GLG Member Program Contributor
- we are in the midst of a worldwide cystal methedrine abuse epidemic - crystal meth can be easily made using ephedrine or pseudephedrine -   commonly used decongestants - in response to this epidemic the U.S. has already passed similar laws   to what has just been passed in the UK - expect...
Posted August 31, 2007
Good device but not much improvement.
Analysis of: St. Jude Medical Announces Japanese Approval Of The Angio-Seal STS Plus Vascular Closure Device | www.medicalnewstoday.com
Author: Ramin Ebrahimi, Director of Cardiac Catheterization Lab Wadsworth VA Medical Center
The repositioning of the hole, also present with the VIP version is a mild improvement to decrease sheath manipulation. Otherwise the device has not changed much in the past few years. While a very good device in general, its primary limitaions listed below still remain. 1. not allowing re-access...
Posted August 31, 2007
New antihistamine gets FDA green light.(RX CARE)(Levocetirizine (Xyzal) by UCB Inc. and Sanofi-Aventis )
Analysis of: New antihistamine gets FDA green light.(RX CARE)(Levocetirizine (Xyzal) by UCB Inc. and Sanofi-Aventis ) | www.therapeuticsdaily.com
Author: GLG Member Program Contributor
A "best-seller" anti-H1 in Europe finally arrives to USA
Posted August 30, 2007
Xyzal approval
Analysis of: New antihistamine gets FDA green light.(RX CARE)(Levocetirizine (Xyzal) by UCB Inc. and Sanofi-Aventis ) | www.therapeuticsdaily.com
Author: Mitchell Boxer, Assistant Clinical Professor Albert Einstein College of Medicine
Zyrtec will soon be available over the counter and this new product will attempt to keep the antihistamine market share for Sanofi-Aventis - although Zyrtec is presently manufactured by Pfizer.  The antihistamine market is quite large and the OTC versus prescription situation is making this problematic...
Posted August 28, 2007
St. Jude Medical Announces Japanese Approval Of The Angio-Seal STS Plus Vascular Closure Device
Analysis of: St. Jude Medical Announces Japanese Approval Of The Angio-Seal STS Plus Vascular Closure Device | www.medicalnewstoday.com
Author: GLG Member Program Contributor
The key implications remain 1)Safety 2)Efficacy 3)Cost 4)Complications e)Outcome analysis
Posted August 28, 2007
Survey: Did the FDA Jump the Gun on PPIs?
Analysis of: Survey: Did the FDA Jump the Gun on PPIs? | www.medpagetoday.com
Author: GLG Member Program Contributor
The frequency of proton pump inhibitors (PPI) prescriptions make FDA review an important step in the long-term assessments of their risk-benefit profile.  It is important to recognize that the FDA did not change the prescribing indications or even issue a warning to physicians about the use of...
Posted August 28, 2007
The drug patent "shell game"
Analysis of: New antihistamine gets FDA green light.(RX CARE)(Levocetirizine (Xyzal) by UCB Inc. and Sanofi-Aventis ) | www.therapeuticsdaily.com
Author: Forrest Rubenstein, Cardiac, Thoracic and Vascular Surgeon Rubenstein Cardiovascular and Thoracic Surgery
   Zyrtec (cetirizine) is a second generation nonsedating antihistamine that has enjoyed wide popularity.  Zyrtec will become available generically in late 2007 and the generic form is expected to be significantly cheaper.  To virtually extend the patent, the manufacturer is...
Previous Page : 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 Next161 to 170 of 395

GLG News: What Experts Think Is Important





Analytics


Generated at 2008-09-06T21:45:17.077